SAJA Pharmaceuticals

Business Insights

Breckenridge Pharmaceutical, Inc. | April 23, 2022

Breckenridge Pharmaceutical, Inc. announces today that it has signed a new-product agreement with PTS Pharma, LLC. under which PTS will support a technology transfer to Towa Pharmaceutical Europe, S.L. of a complex "For Suspension" product developed by PTS. The remainder of development and commercialization will be performed at the Towa facility. According to industry sales data, the product and its generics had annual sales of approximately $75 million during the twelve mo...

Pharma Tech

Lantheus | February 07, 2023

On February 6, 2023, Lantheus Holdings, Inc. (Lantheus), a company dedicated to improving patient outcomes through radiotherapy, diagnostics, and AI solutions that help clinicians to Find, Fight, and Follow® diseases, announced the acquisition of Cerveau Technologies, Inc. (Cerveau). Cerveau's primary asset is MK-6240, which is a second-gen F 18-labeled positron emission tomography (PET) imaging agent that targets Tau tangles present in Alzheimer's disease. ...

Fiercepharma | April 29, 2020

As headlines multiplied and analysts began sussing out Gilead Sciences' first controlled trial readout on remdesivir, NIAID director Anthony Fauci hailed the drug as real progress against the virus. Meanwhile, word emerged that the Trump administration is working up a Manhattan Project style vaccine initiative, bringing biotech, pharma and federal agencies together to speed up the work—and let the U.S. government take on the financial risks. Plus, Pfizer and BioNTech said they've d...

Business Insights

Veeva Systems | October 07, 2021

Veeva Systems (NYSE: VEEV ) announced that Celerion has launched Veeva eConsent , a MyVeeva for Patients solution, to provide electronic consent for its Phase I clinical trials obtain. With Veeva eConsent, Celerion is moving from manual and paper-based consent forms to a fully digital process. The company uses Veeva eConsent for several studies and has already given their consent to more than 200 test subjects. Covid-19 limited the time we cou...